Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) (TINGLE)
Pain, Postoperative, Crohn Disease, Inflammatory Bowel Diseases
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring transversus abdominis plane block, tap block, liposomal bupivacaine, exparel, dexamethasone, colorectal surgery, regional anesthesia, bupivacaine, surgery, postoperative pain, pain
Eligibility Criteria
Inclusion Criteria:
- Male or Female
- Undergoing major laparoscopic colorectal procedure
- Willingness and ability to sign an informed consent document
- No allergies to anesthetic or analgesic medications
- ASA physical status Class I - III
- Aged 18-90 years
Exclusion Criteria:
- Refusal to participate in the study
- Age <18 or > 90 years
- Pregnancy
Contraindications to regional anesthetic including but not limited to:
- Patient refusal to regional field blockade
- Allergy
- Infection at the site of needle insertion
- Systemic infection
- Bleeding diathesis or coagulopathy (as diagnosed by history or laboratory evaluation)
- Liver or renal disease (SCr > 1.5)
- Chronic opioid use
Sites / Locations
- Cedars Sinai Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Bupivacaine/epinephrine/dexamethasone TAP block
Liposomal bupivacaine TAP block
For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.